Skip to search boxSkip to navigationSkip to main content

Telomerase activity in preleukemia and acute myelogenous leukemia

  • Biaoru Li
    ,
  • Jie Yang
    ,
  • Colleen Andrews
    ,
  • Yi Xin Chen
    ,
  • Paul Toofanfard
    ,
  • Ray Win Huang
*Corresponding author for this work
  • Rush University
Scholary Output:
Contribution to journal
Article
Peer-review

Sustainable Development Goals

  • SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well

Abstract

The development of acute leukemia from preleukemia involves the appearance of clones with increasing proliferative potential. The studies described here demonstrate that telomerase activity progressively increases as the bone marrow cells acquire increasing proliferative potential. This was demonstrated by measuring telomerase activity in normal bone marrow, in post-treatment lymphoma marrows with skewed Lyonization, and in MDS and AML marrows. The greater telomerase activity in myelodysplastic marrow than in normal marrow is not due to a higher proportion of blast cells or to a higher proliferative rate of the MDS marrow. These data demonstrate that the increasing proliferative potential of the marrow which occurs during the development of AML is associated with a simultaneous increase in telomerase activity.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 579-587 (9 pages)

Journal (Volume, Issue Number)

Leukemia and Lymphoma (Volume 36, Issue 5-6)

Publication milestones

  • Published - 2000

Publication status

Published - 2000

ISSN

1042-8194

Publication IDs

  • Scopus: 0033967047
  • PubMed: 10784403

Publication metrics

Metrics

Scopus
citations
SciVal
FWCI
1.54
SciVal
Author count
10
SciVal
citations
23
SciVal
Paper percentile
71
Fractional count
1
Fractional count
0.10
Fractional count
9
Fractional count
0.90
Fractional count
1
Fractional count
1

PlumX, opens in new tab

Citation count
23
Captures
6

Funding Details

This work is supported by the National Institute of HealtldNational Cancer Institute RO 1 CA60086, POl-CA7560Wl and partial support by the Coleman Foundation
FundersFunding numbers
National Institute of HealtldNational Cancer Institute
RO 1 CA60086
NCI
P01CA075606
Coleman Foundation
-